Abstract 4302
Background
Breast cancer in men is rare, assuming less than 1% of diagnosed breast cancer, requiring extrapolation of results from studies in women. Our objective is to evaluate prognostic and therapeutic factors paying special attention to the effect of hormonal treatment on the evolution of the disease.
Methods
Observational, retrospective, single-center study of 53 men with breast cancer treated between January 1997 and December 2018. The median follow-up was 66 months (range, 3-282 months). 48 patients had ECOG 0-1 (90.6%), 48 were hormone-receptor-positive (90.5%) and 4 HER2-positive (7.5%). 30 patients had lymph node involvement at diagnosis (56.6%). A total of 45 patients (84.9%) were treated with endocrine therapy (ET) of which 36 received it in adjuvant (67.9%) and 13 in metastatic phase (24.5%). 26 (49.1%) were treated with chemotherapy and 3 with cyclin-dependent kinase inhibitors (5.6%). The association analysis was performed using the Chi-square test and survival analysis with the Log-Rank test in SPSS v25.
Results
Our cohort had a median age of 68 years (range, 40-88 years). 84% had local or locally advanced stage. The infiltrative histologies were 88.7%. The BRCA gen test was carried out in 43.4%, which was positive in 26.1% of the analyzed patients, with BRCA2 being associated with lower mortality (p = 0.004). The statistic analysis showed greater 5-year overall survival (OS) and cancer-specific survival for ECOG 0-1 (p = 0.010, p = 0.048), absence of vascular invasion (p = 0.033, p = 0.025), Ki67 <14% (p = 0.041; p = 0.029) and absence of metastasis at diagnosis (p < 0.0001, p < 0.0001). In relation to ET, they had higher 5-year disease-free survival (OR 0.35, p = 0.001), and lower risk of distant relapse (OR 0.56, p = 0.034) those who received adjuvant ET ≥ 5 years, as well as lower risk of relapse at distance if they received LHRH agonists (OR 0.37, p = 0.022).
Conclusions
The existence of prognostic factors already described in breast cancer in women also seem to be associated with men. The BRCA2 mutation could have a significant role as a predictive marker in males in the near future. ET helps reducing the risk of relapse, particularly at distance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F.J. Salvador Bofil: Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis M. Ruiz Borrego: Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
3180 - Genomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature.
Presenter: Lunda Gu
Session: Poster Display session 2
Resources:
Abstract
4891 - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis
Presenter: Masayuki Ueno
Session: Poster Display session 2
Resources:
Abstract
3203 - Exploratory analysis based on tumor location and early metabolic tumor response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumors.
Presenter: Anne Demols
Session: Poster Display session 2
Resources:
Abstract
1602 - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2848 - Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
1396 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1139 - Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study
Presenter: Andrea Casadei-gardini
Session: Poster Display session 2
Resources:
Abstract
4688 - Prognostic and predictive factors from the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Tim Meyer
Session: Poster Display session 2
Resources:
Abstract
1492 - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
Presenter: David Pinato
Session: Poster Display session 2
Resources:
Abstract
3159 - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study
Presenter: AiPing Zhou
Session: Poster Display session 2
Resources:
Abstract